Aethlon Medical Reports Fiscal Year 2026 Results: Key Study Milestones, Financial Performance, and Strategic Updates
Summary of Key Developments
- Australian Oncology Study Advances to Final Cohort: The company’s ongoing clinical trial in Australia reached a significant milestone by entering the third and final dosing cohort, with the first patient in this group successfully receiving three Hemopurifier treatments over a one-week period. No device deficiencies or immediate complications were reported, and the patient is currently in the follow-up phase. Enrollment continues at three sites, moving the company closer to completing the study and generating data to determine the optimal dosing regimen for patients with solid tumors who have not responded to or have progressed while on anti-PD-1 therapies Keytruda® or Opdivo®.
- Preclinical Research Expansion: Aethlon is broadening the scope of its Hemopurifier platform with preclinical studies targeting additional disease areas, including rheumatoid arthritis and chronic kidney disease. Early research is assessing the device’s ability to remove extracellular vesicles (EVs) from patient plasma samples in these conditions, potentially opening large new market opportunities.
- Intellectual Property Portfolio Strengthened: The company was granted new patents in the U.S. and Europe, extending Hemopurifier’s protection into the 2040s for applications against coronavirus-related conditions, including coagulopathy in acute COVID-19 and symptoms of Long COVID. This extension enhances the long-term value and commercial potential of the platform.
- Operational Discipline: Management maintained a focus on cost control, reducing total operating expenses by nearly 22% year-over-year, which contributed to a significant narrowing of operating and net losses.
- Balance Sheet Update: As of March 31, 2026, Aethlon had \$5.0 million in cash and cash equivalents. Post year-end, the company raised an additional \$1.85 million via its at-the-market (ATM) program, further strengthening its financial position to support ongoing R&D and clinical activities.
Detailed Clinical and Corporate Updates
Australian Oncology Study Milestones
The clinical trial in Australia is designed to evaluate the safety, feasibility, and optimal dosing of the Hemopurifier in patients with solid tumors whose disease is stable or progressing while on immune checkpoint inhibitors. The first two dosing cohorts are complete, and the company has commenced enrollment and treatment in the pivotal third cohort (3-6 participants receiving three treatments in one week). Serial measurements of extracellular vesicles and T cell parameters are being collected, with formal statistical analysis planned upon study completion. The trial’s outcome is expected to guide future development decisions and inform regulatory strategies.
Platform Expansion and Preclinical Research
Beyond oncology, Aethlon is investing in preclinical studies to assess the Hemopurifier’s utility in removing pathogenic EVs in rheumatoid arthritis and chronic kidney disease. These new indications may significantly broaden the addressable market and could become value drivers if successful.
The company is also collaborating with Stavro Medical to test Hemopurifier compatibility with a simplified blood treatment system, aiming to expand potential treatment settings and improve scalability and accessibility if validated.
Intellectual Property Developments
Patents issued in both the U.S. and Europe cover new uses of the Hemopurifier in COVID-19-induced coagulopathy and Long COVID. This extended patent protection into the 2040s may deter competition and increase the commercial attractiveness of the platform for partnerships or acquisition.
Ebola and Emerging Pathogen Preparedness
Following renewed global interest in Ebola outbreaks, Aethlon’s experience with Hemopurifier treatment of an Ebola patient (as highlighted in IEEE Spectrum) was shared with the World Health Organization and the National Emerging Special Pathogen Training and Education Center. The company’s FDA-authorized expanded access protocol for the Hemopurifier remains available, positioning Aethlon as a resource in future public health emergencies.
Financial Performance for Fiscal Year Ended March 31, 2026
- Cash and Liquidity: \$5.0 million in cash and cash equivalents as of year-end, plus \$1.85 million raised post-year-end via ATM program.
- Operating Expenses: Down 21.9% year-over-year to \$7.3 million, driven by reductions in payroll (\$1.1 million), general and administrative expenses (\$500,000), and professional fees (\$400,000).
- Operating Loss: Decreased to \$7.3 million from \$9.3 million in the prior year.
- Net Loss: Narrowed sharply to \$7.2 million from \$13.4 million in the prior year, also reflecting a prior-year \$4.7 million in non-cash financing charges that did not recur.
- Shares Outstanding: 1,570,449 as of March 31, 2026, up from 201,074 a year earlier, reflecting capital raises.
Potential Price-Sensitive Information
- Progression to Final Cohort in Oncology Trial: A major clinical milestone that, if successful, could provide data supporting regulatory advancement and commercial partnering discussions.
- Intellectual Property Advances: New patents for COVID-19 and Long COVID applications significantly extend the commercial runway and may enhance company valuation.
- Cost Reductions and Improved Loss Profile: Demonstrates management’s operational discipline, which may increase investor confidence.
- Additional Capital Raised: The post-year-end ATM raise improves liquidity, reducing near-term going concern risk but also increases shares outstanding and potential dilution.
- Emerging Pathogen Preparedness: Continued relevance in public health initiatives (Ebola, COVID-19, Long COVID) could drive future non-dilutive funding or partnership opportunities.
Conference Call Details
Management will host a conference call on Wednesday, June 10, 2026, at 4:30 p.m. ET to discuss these results. Investors can pre-register or dial in for live or replay access.
About the Hemopurifier®
The Hemopurifier is an investigational medical device that selectively removes enveloped viruses and tumor-derived extracellular vesicles from circulation. It has been granted Breakthrough Device Designation by the FDA for use in advanced cancer and in life-threatening viral infections without approved therapies.
About Aethlon Medical, Inc.
Aethlon Medical (Nasdaq: AEMD) is a clinical-stage medical device company based in San Diego, California, focused on developing the Hemopurifier platform to address unmet needs in oncology and infectious disease.
Disclaimer
This article contains forward-looking statements based on current expectations and subject to risks and uncertainties, including clinical trial outcomes, regulatory approvals, capital needs, and market acceptance. The Hemopurifier is an investigational device; its safety and efficacy have not been established. Investors should review the company’s SEC filings and consult with a financial advisor before making investment decisions. This is not a solicitation to buy or sell securities.
